Hidradenitis suppurativa (HS) highlights from AAD 2025 include studies of HS patients' risk for cardiovascular disease or ...
Dr. Christopher J. Sayed shares insights on the growing emphasis on personalized care for hidradenitis suppurativa.
Posters presented at the 2025 American Academy of Dermatology Annual Meeting found tildrakizumab outcomes to have a mean drug ...
A panelist discusses how new data from the 2025 American Academy of Dermatology Annual Meeting (AAD 2025) demonstrates tildrakizumab’s efficacy in treating nail psoriasis, with the 100-mg dose showing ...
HealthDay on MSN13d
American Academy of Dermatology, March 7 to 11The annual meeting of the American Academy of Dermatology was held from March 7 to 11 in Orlando, Florida, and attracted ...
Patients with skin disease adhering to a proper diet may experience better treatment responses and a reduced risk of adverse ...
Patients with hidradenitis suppurativa are at increased risk of developing several common inflammatory arthropathies in the years following diagnosis.
Many patients who achieved clear skin with tapinarof treatment maintained low disease activity after a treatment-free interval.
Galderma will present updates from across its broad dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7-11, 2025 in Orlando, Florida.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback